Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells Retraction in /10.3892/ijo.2023.5547

Tian,Feng; Ding,Ding; Li,Dandan

doi:10.3892/ijo.2015.2959

Fangchinoline targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901 cells

Retraction in: /10.3892/ijo.2023.5547

Authors:
- Feng Tian
- Ding Ding
- Dandan Li
View Affiliations

Affiliations: Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: April 9, 2015 https://doi.org/10.3892/ijo.2015.2959
Pages: 2355-2363
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fangchinoline, an important compound in Stephania tetrandra S. Moore, as a novel antitumor agent, has been implicated in several types of cancers cells except gastric cancer. To investigate whether fangchinoline affects gastric cancer cells, we detected the signaling pathway by which fangchinoline plays a role in different human gastric cancer cells lines. We found that fangchinoline effectively suppressed proliferation and invasion of SGC7901 cell lines, but not MKN45 cell lines by inhibiting the expression of PI3K and its downstream pathway. All of the Akt/MMP2/MMP9 pathway, Akt/Bad pathway, and Akt/Gsk3β/CDK2 pathway could be inhibited by fangchinoline through inhibition of PI3K. Taken together, these results suggest that fangchinoline targets PI3K in tumor cells that express PI3K abundantly and inhibits the growth and invasive ability of the tumor cells.

View Figures

View References

1	Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM and Giordano S: Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer. 9:1212010. View Article : Google Scholar : PubMed/NCBI
2	Solit DB, Basso AD, Olshen AB, Scher HI and Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 63:2139–2144. 2003.PubMed/NCBI
3	Kazlauskas A and Cooper JA: Phosphorylation of the PDGF receptor beta subunit creates a tight binding site for phosphatidylinositol 3 kinase. EMBO J. 9:3279–3286. 1990.PubMed/NCBI
4	Chiang EP, Tsai SY, Kuo YH, Pai MH, Chiu HL, Rodriguez RL and Tang FY: Caffeic acid derivatives inhibit the growth of colon cancer: Involvement of the PI3-K/Akt and AMPK signaling pathways. PLoS One. 9:e996312014. View Article : Google Scholar : PubMed/NCBI
5	Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, et al: Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA. 106:2835–2840. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wang QS, Papanikolaou A, Sabourin CL and Rosenberg DW: Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Carcinogenesis. 19:2001–2006. 1998. View Article : Google Scholar : PubMed/NCBI
8	Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB and Rosen N: PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res. 70:6804–6814. 2010. View Article : Google Scholar : PubMed/NCBI
9	Dienstmann R, Rodon J, Serra V and Tabernero J: Picking the point of inhibition: A comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 13:1021–1031. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wang Y, Chen J, Wang L, Huang Y, Leng Y and Wang G: Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells. Exp Ther Med. 5:1105–1112. 2013.PubMed/NCBI
11	Nakamura K, Tsuchiya S, Sugimoto Y, Sugimura Y and Yamada Y: Histamine release inhibition activity of bisbenzylisoquinoline alkaloids. Planta Med. 58:505–508. 1992. View Article : Google Scholar : PubMed/NCBI
12	Kim HS, Zhang YH, Oh KW and Ahn HY: Vasodilating and hypotensive effects of fangchinoline and tetrandrine on the rat aorta and the stroke-prone spontaneously hypertensive rat. J Ethnopharmacol. 58:117–123. 1997. View Article : Google Scholar : PubMed/NCBI
13	Hristova M and Istatkova R: Complement-mediated antiinflammatory effect of bisbenzylisoquinoline alkaloid fangchinoline. Phytomedicine. 6:357–362. 1999. View Article : Google Scholar
14	Choi HS, Kim HS, Min KR, Kim Y, Lim HK, Chang YK and Chung MW: Anti-inflammatory effects of fangchinoline and tetrandrine. J Ethnopharmacol. 69:173–179. 2000. View Article : Google Scholar : PubMed/NCBI
15	Shen YC, Chou CJ, Chiou WF and Chen CF: Anti-inflammatory effects of the partially purified extract of radix Stephaniae tetrandrae: Comparative studies of its active principles tetrandrine and fangchinoline on human polymorphonuclear leukocyte functions. Mol Pharmacol. 60:1083–1090. 2001.PubMed/NCBI
16	Kim HS, Zhang YH and Yun YP: Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation. Planta Med. 65:135–138. 1999. View Article : Google Scholar : PubMed/NCBI
17	Tsutsumi T, Kobayashi S, Liu YY and Kontani H: Antihyperglycemic effect of fangchinoline isolated from Stephania tetrandra Radix in streptozotocin-diabetic mice. Biol Pharm Bull. 26:313–317. 2003. View Article : Google Scholar : PubMed/NCBI
18	Ma W, Nomura M, Takahashi-Nishioka T and Kobayashi S: Combined effects of fangchinoline from Stephania tetrandra Radix and formononetin and calycosin from Astragalus membranaceus Radix on hyperglycemia and hypoinsulinemia in streptozotocin-diabetic mice. Biol Pharm Bull. 30:2079–2083. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lin TY, Lu CW, Tien LT, Chuang SH, Wang YR, Chang WH and Wang SJ: Fangchinoline inhibits glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neurochem Int. 54:506–512. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gülçin I, Elias R, Gepdiremen A, Chea A and Topal F: Antioxidant activity of bisbenzylisoquinoline alkaloids from Stephania rotunda: Cepharanthine and fangchinoline. J Enzyme Inhib Med Chem. 25:44–53. 2010. View Article : Google Scholar
21	Sekiya N, Hikiami H, Yokoyama K, Kouta K, Sakakibara I, Shimada Y and Terasawa K: Inhibitory effects of Stephania tetrandra S. Moore on free radical-induced lysis of rat red blood cells. Biol Pharm Bull. 28:667–670. 2005. View Article : Google Scholar : PubMed/NCBI
22	Zhang YH, Fang LH and Ku BS: Fangchinoline inhibits rat aortic vascular smooth muscle cell proliferation and cell cycle progression through inhibition of ERK1/2 activation and c-fos expression. Biochem Pharmacol. 66:1853–1860. 2003. View Article : Google Scholar : PubMed/NCBI
23	Meng LH, Zhang H, Hayward L, Takemura H, Shao RG and Pommier Y: Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res. 64:9086–9092. 2004. View Article : Google Scholar : PubMed/NCBI
24	Sun X, Xu R, Deng Y, Cheng H, Ma J, Ji J and Zhou Y: Effects of tetrandrine on apoptosis and radiosensitivity of nasopharyngeal carcinoma cell line CNE. Acta Biochim Biophys Sin (Shanghai). 39:869–878. 2007. View Article : Google Scholar
25	Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G and Feng Y: Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol. 164(2b): 731–742. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wang CD, Yuan CF, Bu YQ, Wu XM, Wan JY, Zhang L, Hu N, Liu XJ, Zu Y, Liu GL, et al: Fangchinoline inhibits cell proliferation via Akt/GSK-3beta/cyclin D1 signaling and induces apoptosis in MDA-MB-231 breast cancer cells. Asian Pac J Cancer Prev. 15:769–773. 2014. View Article : Google Scholar
27	Xing Z, Zhang Y, Zhang X, Yang Y, Ma Y and Pang D: Fangchinoline induces G1 arrest in breast cancer cells through cell-cycle regulation. Phytother Res. 27:1790–1794. 2013. View Article : Google Scholar : PubMed/NCBI
28	Xing ZB, Yao L, Zhang GQ, Zhang XY, Zhang YX and Pang D: Fangchinoline inhibits breast adenocarcinoma proliferation by inducing apoptosis. Chem Pharm Bull (Tokyo). 59:1476–1480. 2011. View Article : Google Scholar
29	Sun HW, Tong SL, He J, Wang Q, Zou L, Ma SJ, Tan HY, Luo JF and Wu HX: RhoA and RhoC -siRNA inhibit the proliferation and invasiveness activity of human gastric carcinoma by Rho/PI3K/Akt pathway. World J Gastroenterol. 13:3517–3522. 2007. View Article : Google Scholar : PubMed/NCBI
30	Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JC, et al: Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol. 18:378–386. 2008. View Article : Google Scholar : PubMed/NCBI
31	Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, et al: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67:5840–5850. 2007. View Article : Google Scholar : PubMed/NCBI
32	Leung E, Kim JE, Rewcastle GW, Finlay GJ and Baguley BC: Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol Ther. 11:938–946. 2011. View Article : Google Scholar : PubMed/NCBI
33	Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 287:821–828. 1999. View Article : Google Scholar : PubMed/NCBI
34	Graña X and Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
35	Prasad R, Vaid M and Katiyar SK: Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One. 7:e430642012. View Article : Google Scholar : PubMed/NCBI
36	Gan B, Yoo Y and Guan JL: Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth. J Biol Chem. 281:37321–37329. 2006. View Article : Google Scholar : PubMed/NCBI
37	Schlaepfer DD and Hunter T: Signal transduction from the extracellular matrix - a role for the focal adhesion protein-tyrosine kinase FAK. Cell Struct Funct. 21:445–450. 1996. View Article : Google Scholar : PubMed/NCBI
38	Zhao J and Guan JL: Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 28:35–49. 2009. View Article : Google Scholar : PubMed/NCBI
39	Hara T, Miyazaki H, Lee A, Tran CP and Reiter RE: Androgen receptor and invasion in prostate cancer. Cancer Res. 68:1128–1135. 2008. View Article : Google Scholar : PubMed/NCBI
40	Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA and Mazzarino C: Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). Int J Oncol. 34:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
41	Kanaki T, Bujo H, Mori S, Yanjuan Z, Takahashi K, Yokote K, Morisaki N and Saito Y: Functional analysis of aortic endothelial cells expressing mutant PDGF receptors with respect to expression of matrix metalloproteinase-3. Biochem Biophys Res Commun. 294:231–237. 2002. View Article : Google Scholar : PubMed/NCBI